Evaluate Companies

 
News Articles for Evaluate Companies top ^
Evaluation module features smallest, brightest and most efficient DLP® Pico™ WVGA display chipset DALLAS , Aug.
Sign-up for TI announces first DLP® LightCrafter™ evaluation module for video and data display applications investment picks
2014/8/13
Target date funds vary widely in their approach, making it all the more critical that retirement plan sponsors and advisors monitor them regularly to confirm they are performing as expected.
Sign-up for Wells Fargo Advantage Funds White Paper Gives Plan Sponsors and Advisors New Tools for Evaluating Target Date Fund Performance investment picks
Feature-rich, affordable platform enables OEMs to leverage SmartFusion2's lowest power consumption in its class, high reliability capabilities and best-in-class security to build highly differentiated products with significant time to market advantage ALISO VIEJO, Calif.
Sign-up for Microsemi Enables OEMs to Expedite Prototyping and Application Development with its Comprehensive New SmartFusion2 SoC FPGA Evaluation Kit investment picks
Emerson (NYSE: EMR) today announced that it is evaluating strategic alternatives for its Power Transmission Solutions business unit.
Sign-up for Emerson Evaluating Strategic Alternatives for the Power Transmission Solutions Business investment picks
ACI Worldwide (NASDAQ: ACIW), a leading international provider of electronic payment and banking solutions , has been recognized as an industry leader by Aite Group, an independent research firm, in its recent report, “2014 Evaluation of Leading Cash Management Providers.” According to the report, “the U.S. cash management industry is ready for change, and investment in the online and mobile channels is critical to future success.” ACI has seen considerable momentum for its online banking platform, and as the report notes, ACI had the highest number of customers in terms of large and midsize U.S. banks (banks with greater than US$10 billion in assets). ACI recently announced that Webster Bank, a leading regional bank in the Northeast with $21 billion in assets, has selected the company to host its online banking platform.
Sign-up for ACI Worldwide Recognized as Industry Leader in Aite Group’s Evaluation of Leading Cash Management Providers investment picks
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer investment picks
2014/8/19
Pacific Rubiales Announces a 45% Increase in Certified Total Prospective Resources and a 62% Increase in Certified Contingent Resources, in an Evaluation of its Exploration Blocks Canada NewsWire   SOURCE Pacific Rubiales Energy Corp.
Sign-up for Pacific Rubiales Announces a 45% Increase in Certified Total Prospective Resources and a 62% Increase in Certified Contingent Resources, in an Evaluation of its Exploration Blocks investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 – 30.
Sign-up for Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014 investment picks
PRINCETON, N.J., June 16, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS) , a clinical-stage biotechnology company developing cancer immunotherapies, announced that the Georgia Regents University (GRU) Cancer Center has received Institutional Review Board (IRB) approval to initiate a Phase 1/2 trial evaluating higher doses and repeat cycles of ADXS-HPV in patients with recurrent cervical cancer.
Sign-up for Advaxis Evaluates Higher Dose and Repeat Cycles of ADXS-HPV in Phase 1/2 Cervical Cancer Trial investment picks
Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED ® technology and materials, today announced an expanded evaluation agreement with BOE Technology Group Co., Ltd.
Sign-up for BOE Technology Group Expands Evaluation Partnership with Universal Display Corporation investment picks
RF430F5978 MCU integrates TI sub-1GHz RF transceiver, 3D LF wake-up trigger and transponder with standard MSP430 MCU features and advanced AES security DALLAS , July 15, 2014 /PRNewswire/ -- Expanding its broad portfolio of low-power, radio frequency (RF) solutions, Texas Instruments (TI) (NASDAQ: TXN) today introduces the RF430F5978 microcontroller (MCU) and accompanying evaluation module (EVM). Building on TI's CC430 product family, the RF430F5978 MCU is a highly integrated RF solution with improved read zone and battery performance for ultra-low power applications.
Sign-up for TI introduces its latest RF430 security MCU with highest RF integration in the industry; new evaluation module jumpstarts designs investment picks
Celgene Corporation (NASDAQ:CELG) today announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with active ankylosing spondylitis.
Sign-up for Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis investment picks
LONDON , July 8, 2014 /PRNewswire/ -- Northrop Grumman Corporation (NYSE: NOC) has participated in Unified Vision 2014 (UV14), NATO's largest trial of Joint Intelligence, Surveillance and Reconnaissance (JISR) capability aimed at demonstrating and evaluating the Alliance's ability to coordinate and deploy crucial Allied ISR systems.
Sign-up for Global Hawk Takes Part in NATO Exercise to Evaluate Joint Intelligence, Surveillance and Reconnaissance Capability investment picks
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patient has been dosed in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot ® Testosterone (QS T) administered subcutaneously once each week to testosterone-deficient adult males.
Sign-up for Antares Pharma Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males investment picks
Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech’s PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer (NSCLC). Both INCB24360 and MPDL3280A are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body’s own defenses in fighting cancer; both agents target distinct regulatory components of the immune system.
Sign-up for Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies investment picks
Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin's lymphoma Results of study will be optimized by CGI to validate and enhance their proprietary genomic panel for DLBCL RUTHERFORD, N.J., Aug.
Sign-up for Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma investment picks
Red Hat, Inc. (NYSE: RHT), the world's leading provider of open source solutions, today announced Open Virtual Appliance for Red Hat Enterprise Linux OpenStack Platform, enabling organizations with VMware-based infrastructures to easily and rapidly deploy and evaluate Red Hat Enterprise Linux OpenStack Platform for proof of concept deployments.
Sign-up for Red Hat Introduces Open Virtual Appliance for Seamless OpenStack Evaluations investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, OPDIVO ( nivolumab), and Celgene’s nab ® technology-based chemotherapy ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a Phase I study.
Sign-up for Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen investment picks
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 - PIONEER I first Phase 3 trial to evaluate the investigational use of HUMIRA in patients with moderate-to-severe HS3 - Results show HUMIRA meets primary endpoint3 COPENHAGEN, Denmark , Sept.
Sign-up for AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Evaluate Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: European Stocks  |  Next: Event Management